GSK executive caught off-guard by China graft charges: sources

By Adam Jourdan and Kazunori Takada SHANGHAI (Reuters) – GlaxoSmithKline Plc executive Mark Reilly had little inkling he would be charged with leading a network of corruption in China's pharmaceutical industry, two sources with ties to the businessman and knowledge of the investigation said. The allegations against the Briton, who as GSK's China head was the firm's legal representative in the country, are the most serious charges ever laid against a foreign national for corporate corruption in China, lawyers said. \"The fact that Mark's name was on the list of people charged was definitely a surprise,\" said a source with direct knowledge of the investigation. Britain's biggest drugmaker said in a statement on Wednesday that the allegations were \"deeply concerning\" and it hoped to \"reach a resolution\" that would enable it to continue to operate in China, a key growth market for Western pharmaceutical giants.